An RSVP is required for this program.

In what sounds like a bad April Fool’s Day joke, the Minnesota legislature has proposed a bill ostensibly banning “human cloning” but actually directed at prohibiting the use of embryonic stem cells. For those who thought the fight was over, it is clear that the battle is on-going.

Join Nixon Peabody on May 20 for our Sixth Annual Stem Cell Conference as we place these events and more in context.

Keynote Speaker:

M. William “Willy” Lensch, PhD, Instructor in Pediatrics, Harvard Medical School, Affiliate Faculty and Faculty Advisor for Education, Harvard Stem Cell Institute
Do We Still Need Embryonic Stem Cells or Has the Research Passed Them By?

Featured Speakers:

Rekha K. Paleyanda, Ph.D., Senior Business Strategy and Licensing Manager, Massachusetts General Hospital, Partners HealthCare | Research Ventures & Licensing
The Challenge of Licensing Early Stage Regenerative Medicine and Stem Cell Patents

Susan R. Windham-Bannister, Ph.D., President and CEO, Massachusetts Life Sciences Center
Massachusetts’ Efforts to Fund Life Science Companies in Economically Challenging Times

Ankit Mahadevia, Principal, Atlas Venture, Life Sciences Group
The Reality of Funding Regenerative Medicine Companies, Including Stem Cell Companies

Valentin Fulga, M.D., CEO, Hemostemix
Hemostemix’s Stem Cell Based Therapy and Its Plans for the Future

John McNeish, Biopharmaceutical Consultant for Regenerative Medicine, Boston Stem Cell, LLC

Ronald I. Eisenstein, Partner, Nixon Peabody LLP
The Legal Impact That the ACLU’s Attack on Myriad’s Gene Patents and the Recent Suit Against Monsanto’s Genetic Seed Patents Will Have on Stem Cells

David S. Resnick, Partner, Nixon Peabody LLP
The Landscape for Stem Cell Intellectual Property

For more information, please contact Laura Ketchum at 617-345-1297 or lketchum@nixonpeabody.com